Fuelled by the need for more effective treatment options and growing focus of the medical community to develop drugs and therapies that target tumor roots, research in the field of Cancer Stem Cells (CSCs) is attracting increased investments. Stem cells also known as progenitor cells, represent cells that are capable of regenerating malignant tumor cells and thus are responsible for the spread of cancer. As a key cause for tumor recurrence, metastasis, and resistance, cancer stem cells are therefore an important theme for R&D, especially as a drug target. The coming years are forecast to witness the development of novel drugs that target cancer stem cells (CSCs).
In addition to technical growth drivers, key market forces fuelling growth include rising awareness about cancer among the patient base, growing disposable incomes and greater healthcare per capita spends especially in developing countries, establishment of latest healthcare facilities and improvement in quality of care offered, and supportive legislations that encourage R&D investments among big pharma companies by mitigating R&D risk exposure in this space.
The study estimates the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) to be a multi-million dollar market, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.
The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled t
Copyright©2012 Vocus, Inc.
All rights reserved